Expert Review of Clinical Pharmacology最新文献_第9页

Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting? 伊马替尼的治疗药物监测--我们在白血病领域走了多远？

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-03-01 Epub Date: 2024-02-12 DOI: 10.1080/17512433.2024.2312256

Anna Sofie Buhl Rasmussen, Christen Lykkegaard Andersen, Allan Weimann, Tianwu Yang, Camille Tron, Virginie Gandemer, Kim Dalhoff, Cecilie Utke Rank, Kjeld Schmiegelow

{"title":"Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting?","authors":"Anna Sofie Buhl Rasmussen, Christen Lykkegaard Andersen, Allan Weimann, Tianwu Yang, Camille Tron, Virginie Gandemer, Kim Dalhoff, Cecilie Utke Rank, Kjeld Schmiegelow","doi":"10.1080/17512433.2024.2312256","DOIUrl":"10.1080/17512433.2024.2312256","url":null,"abstract":"Introduction: Tyrosine kinase inhibitors (TKIs) have revolutionized survival rates of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) and replaced hematopoietic stem cell transplantation (hSCT) as the key treatment option for these patients. More recently, the so-called Philadelphia chromosome-like (Ph-like) ALL has similarly benefitted from TKIs. However, many patients shift from the first generation TKI, imatinib, due to treatment-related toxicities or lack of treatment efficacy. A more personalized approach to TKI treatment could counteract these challenges and potentially be more cost-effective. Therapeutic drug monitoring (TDM) has led to higher response rates and less treatment-related toxicity in adult CML but is rarely used in ALL or in childhood CML.Areas covered: This review summarizes different antileukemic treatment indications for TKIs with focus on imatinib and its pharmacokinetic/-dynamic properties as well as opportunities and pitfalls of TDM for imatinib treatment in relation to pharmacogenetics and co-medication for pediatric and adult Ph+/Ph-like leukemias.Expert opinion: TDM of imatinib adds value to standard monitoring of ABL-class leukemia by uncovering non-adherence and potentially mitigating adverse effects. Clinically implementable pharmacokinetic/-dynamic models adjusted for relevant pharmacogenetics could improve individual dosing. Prospective trials of TDM-based treatments, including both children and adults, are needed.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The future of pharmacology education: The Veterinary Educators in Pharmacology Special Interest Group (VEPSIG). 药理学教育的未来：兽医药理学教育工作者特别兴趣小组（VEPSIG）。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-03-01 Epub Date: 2024-02-07 DOI: 10.1080/17512433.2024.2315309

Martin Hawes, Arno Werners

引用次数: 0

The effect of different levothyroxine administration regimens on thyroid hormone levels: a systematic review, pairwise, and network meta-analysis. 甲状腺功能减退症中的左甲状腺素给药方案不同左甲状腺素给药方案对甲状腺激素水平的影响：系统综述、配对分析和网络荟萃分析。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-03-01 Epub Date: 2024-02-05 DOI: 10.1080/17512433.2024.2313616

Bianca Vendruscolo Bianchini, Patricia Romualdo de Jesus, Renato Gorga Bandeira de Mello, Patricia Klarmann Ziegelmann, Kristian Bellevue Filion, Tatiane da Silva Dal Pizzol

{"title":"The effect of different levothyroxine administration regimens on thyroid hormone levels: a systematic review, pairwise, and network meta-analysis.","authors":"Bianca Vendruscolo Bianchini, Patricia Romualdo de Jesus, Renato Gorga Bandeira de Mello, Patricia Klarmann Ziegelmann, Kristian Bellevue Filion, Tatiane da Silva Dal Pizzol","doi":"10.1080/17512433.2024.2313616","DOIUrl":"10.1080/17512433.2024.2313616","url":null,"abstract":"Introduction: This systematic review aimed to compare the effect of alternative levothyroxine administration regimens on thyroid hormone levels and patient-reported outcomes (PROs) among adults with hypothyroidism.Methods: We searched PubMed, Embase, CENTRAL, CINAHL, LILACS, SciELO, Scopus, Web of Science, OpenGrey, ProQuest, ClinicalTrials.gov, and ICTRP from inception to May/2023 for randomized controlled trials (RCTs). We assessed the risk of bias with Cochrane Risk of Bias 2.0 tool. We analyzed TSH levels by pairwise and network meta-analyses (NMA). The FT4 levels and PROs were qualitatively assessed.Results: We included 14 RCTs (906 participants) comparing different regimens, as bedtime vs. before breakfast. A total of 12 RCTs were at high risk of bias. Seven RCTs were included in the TSH meta-analysis, where the mean difference (MD) and 95% confidence interval (CI) were as follows: bedtime vs before breakfast (4 RCTs) 0.69 (-1.67-3.04), I2 = 92%, very low certainty evidence; weekly dose vs before breakfast (2 RCTs) 1.68 (0.94-2.41), I2 = 0%, low certainty evidence; and at breakfast vs before breakfast (1 RCT) 0.65 (-1.11-2.41), very low certainty evidence. The NMA showed no evidence of differences in TSH level with different regimens.Conclusion: The evidence is insufficient to determine the most effective levothyroxine administration regimen for hypothyroidism.Systematic review registration: PROSPERO - CRD42021279375.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight 对乙酰氨基酚肝毒性的生物标志物发现：利用单细胞转录组学和机理洞察力

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-01-13 DOI: 10.1080/17512433.2024.2306219

David S Umbaugh, Hartmut Jaeschke

引用次数: 0

An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations. 桔梗临床药理学的最新进展：用途、滥用潜力和未来考虑。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2024.2305798

Christopher R McCurdy, Abhisheak Sharma, Kirsten E Smith, Charles A Veltri, Stephanie T Weiss, Charles M White, Oliver Grundmann

{"title":"An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations.","authors":"Christopher R McCurdy, Abhisheak Sharma, Kirsten E Smith, Charles A Veltri, Stephanie T Weiss, Charles M White, Oliver Grundmann","doi":"10.1080/17512433.2024.2305798","DOIUrl":"10.1080/17512433.2024.2305798","url":null,"abstract":"Introduction: Kratom (Mitragyna speciosa) has generated substantial clinical and scientific interest as a complex natural product. Its predominant alkaloid mitragynine and several stereoisomers have been studied for activity in opioid, adrenergic, and serotonin receptors. While awaiting clinical trial results, the pre-clinical evidence suggests a range of potential therapeutic applications for kratom with careful consideration of potential adverse effects.Areas covered: The focus of this review is on the pharmacology, pharmacokinetics, and potential drug-drug interactions of kratom and its individual alkaloids. A discussion on the clinical pharmacology and toxicology of kratom is followed by a summary of user surveys and the evolving concepts of tolerance, dependence, and withdrawal associated with kratom use disorder.Expert opinion: With the increasing use of kratom in clinical practice, clinicians should be aware of the potential benefits and adverse effects associated with kratom. While many patients may benefit from kratom use with few or no reported adverse effects, escalating dose and increased use frequency raise the risk for toxic events in the setting of polysubstance use or development of a use disorder.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10846393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population pharmacokinetics of antibacterial agents in the older population: a literature review. 老年人口中抗菌药物的群体药代动力学：文献综述。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-23 DOI: 10.1080/17512433.2023.2295009

Hui-Xin Liu, Bo-Hao Tang, John van den Anker, Guo-Xiang Hao, Wei Zhao, Yi Zheng

{"title":"Population pharmacokinetics of antibacterial agents in the older population: a literature review.","authors":"Hui-Xin Liu, Bo-Hao Tang, John van den Anker, Guo-Xiang Hao, Wei Zhao, Yi Zheng","doi":"10.1080/17512433.2023.2295009","DOIUrl":"10.1080/17512433.2023.2295009","url":null,"abstract":"Introduction: Older individuals face an elevated risk of developing bacterial infections. The optimal use of antibacterial agents in this population is challenging because of age-related physiological alterations, changes in pharmacokinetics (PK) and pharmacodynamics (PD), and the presence of multiple underlying diseases. Therefore, population pharmacokinetics (PPK) studies are of great importance for optimizing individual treatments and prompt identification of potential risk factors.Area covered: Our search involved keywords such as 'elderly,' 'old people,' and 'geriatric,' combined with 'population pharmacokinetics' and 'antibacterial agents.' This comprehensive search yielded 11 categories encompassing 28 antibacterial drugs, including vancomycin, ceftriaxone, meropenem, and linezolid. Out of 127 studies identified, 26 (20.5%) were associated with vancomycin, 14 (11%) with meropenem, and 14 (11%) with piperacillin. Other antibacterial agents were administered less frequently.Expert opinion: PPK studies are invaluable for elucidating the characteristics and relevant factors affecting the PK of antibacterial agents in the older population. Further research is warranted to develop and validate PPK models for antibacterial agents in this vulnerable population.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study. 布景和环境可预测精神病理学、幸福感和迷幻体验的意义：一项相关研究。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2023.2295997

Lucas F Borkel, Jaime Rojas-Hernández, Luis Alberto Henríquez-Hernández, Ángelo Santana Del Pino, Domingo J Quintana-Hernández

{"title":"Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study.","authors":"Lucas F Borkel, Jaime Rojas-Hernández, Luis Alberto Henríquez-Hernández, Ángelo Santana Del Pino, Domingo J Quintana-Hernández","doi":"10.1080/17512433.2023.2295997","DOIUrl":"10.1080/17512433.2023.2295997","url":null,"abstract":"Background: In psychedelic therapy, the importance of set and setting is a fundamental but under-researched assumption. The aim of this study is to correlate variables of set (psychedelic use motivation) and setting (psychedelic use location and type of companion) with psychopathology, wellbeing and personality variables.Research design and methods: A sample of 1022 participants of the Spanish-speaking population was collected through an online survey. A novel instrument, the Psychedelic Use Scale (PUS), was developed to measure substance use variables of LSD, mescaline, psilocybin, DMT, 5-Meo-DMT, ketamine, Salvia divinorum, ibogaine and MDMA. Various personality, well-being and psychopathology instruments were implemented to measure outcome variables.Results: Growth motivations, natural settings and presence of significant others predicted less psychopathology, greater wellbeing and meaningfulness of psychedelic experiences, whereas problematic motivations predicted greater psychopathology, lower wellbeing and did not predict meaningfulness of psychedelic experiences.Conclusions: Based on these results, we suggest experimental hypotheses for future clinical trials and longitudinal studies with potential clinical implications.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138801873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical trial design for assessing hypertension medications: are critical circadian chronopharmacological principles being taking into account? 评估高血压药物的临床试验设计：是否考虑了重要的昼夜时相药理学原则？

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2024.2304015

Ramón C Hermida, Michael H Smolensky, Artemio Mojón, José R Fernández

{"title":"Clinical trial design for assessing hypertension medications: are critical circadian chronopharmacological principles being taking into account?","authors":"Ramón C Hermida, Michael H Smolensky, Artemio Mojón, José R Fernández","doi":"10.1080/17512433.2024.2304015","DOIUrl":"10.1080/17512433.2024.2304015","url":null,"abstract":"Introduction: Clinical hypertension trials typically rely on homeostatic principles, including single time-of-day office blood pressure (BP) measurements (OBPM), rather than circadian chronopharmacological principles, including ambulatory monitoring (ABPM) done around-the-clock to derive the asleep systolic BP (SBP) mean and sleep-time relative SBP decline - jointly the strongest prognosticators of cardiovascular disease (CVD) risk and true definition of hypertension - to qualify participants and assess outcomes.Areas covered: Eight chronopharmacological elements are indispensable for design and conduct of hypertension medication trials, mainly those on ingestion-time differences in effects, and also a means of rating quality of investigations. Accordingly, we highlight the findings and shortcomings of: (i) 155 such ingestion-time trials, 83.9% finding at-bedtime/evening treatment more beneficial than conventional upon-awakening/morning treatment; (ii) HOPE and ONTARGET CVD outcomes investigations assessing in the former add-on ramipril at-bedtime and in the latter telmisartan, ramipril, or both in combination in the morning; and (iii) pragmatic TIME CVD outcomes trial.Expert opinion: Failure to incorporate chronopharmacological principals - including ABPM to derive asleep SBP and SBP dipping to qualify subjects as hypertensive and assess CVD risk - results in deficient study design, dubious findings, and unnecessary medical controversy at the expense of advances in patient care.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The future of pharmacology education: a global outlook. 药理学教育的未来：全球展望。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2024.2302602

Clare Guilding, Roisin Kelly-Laubscher, Paul White

引用次数: 0

Artificial intelligence and machine learning in clinical pharmacological research. 人工智能和机器学习在临床药理研究中的应用。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-23 DOI: 10.1080/17512433.2023.2294005

Benjamin Mayer, Dario Kringel, Jörn Lötsch

{"title":"Artificial intelligence and machine learning in clinical pharmacological research.","authors":"Benjamin Mayer, Dario Kringel, Jörn Lötsch","doi":"10.1080/17512433.2023.2294005","DOIUrl":"10.1080/17512433.2023.2294005","url":null,"abstract":"Background: Clinical pharmacology research has always involved computational analysis. With the abundance of drug-related data available, the integration of artificial intelligence (AI) and machine learning (ML) methods has emerged as a promising way to enhance clinical pharmacology research.Methods: Based on an accepted definition of clinical pharmacology as a field of research dealing with all aspects of drug-human interactions, the analysis included publications from institutes specializing in clinical pharmacology. Research topics and the most used machine learning methods in clinical pharmacology were retrieved from the PubMed database and summarized.Results: ML was identified in 674 publications attributed to clinical pharmacology research, with a significant increase in publication activity over the last decade. Notable research topics addressed by ML/AI included Covid-19-related clinical pharmacology research, clinical neuropharmacology, drug safety and risk assessment, clinical pharmacology related to cancer research, and antimicrobial and antiviral research unrelated to Covid-19. In terms of ML methods, neural networks, random forests, and support vector machines were frequently mentioned in the abstracts of the retrieved papers.Conclusions: ML, and AI in general, is increasingly being used in various research areas within clinical pharmacology. This report presents specific examples of applications and highlights the most used ML methods.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0